LIANY OTC
LianMedical
1W: -2.9%
1M: +45.6%
3M: -47.3%
YTD: -38.7%
1Y: +7.9%
3Y: +698.5%
$0.06
+0.01 (+14.22%)
Weekly Expected Move ±30.6%
$0
$0
$0
$0
$0
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
9 relationships9
As Filer
counterparties named
0
As Counterparty
mentioned by others
4
Rel. Types
2021-11-10
Earliest Filing
2023-12-26
Latest Filing
partner: 6
acquirer: 1
supplier: 1
customer: 1
Counterparties (Filed by LIANY)
9 relationshipsCompanies named in LIANY's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Janssen Pharmaceutica NV | — | acquirer | Acquired rights and interests in NBTXR3 licensed products from LianBio Development | 2023-12-26 | View |
| Nanobiotix S.A. | NBTX | partner | Original licensor of NBTXR3 rights and party to novation agreement | 2023-12-26 | View |
| MyoKardia, Inc. | — | partner | Licensor party in terminated exclusive license agreement for mavacamten | 2023-10-30 | View |
| Bristol-Myers Squibb Company | BMY | partner | Licensor party in terminated exclusive license agreement for mavacamten | 2023-10-30 | View |
| E.R. Squibb & Sons, L.L.C. | — | partner | Licensor party in terminated exclusive license agreement for mavacamten | 2023-10-30 | View |
| Swords Laboratories Unlimited Company | — | partner | Licensor party in terminated exclusive license agreement for mavacamten | 2023-10-30 | View |
| QED Therapeutics, Inc. | — | partner | Party to terminated Amended and Restated Option Agreement | 2023-10-30 | View |
| Shanghai Xingqiao Real Estate Co., Ltd. | — | supplier | Lessor of office space under a lease agreement | 2021-11-10 | View |
| Shanghai LianBio Development Co., Ltd. | — | customer | Lessee of office space under a lease agreement | 2021-11-10 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2024-02-13 | Costs Associated with Exit or Disposal Activities; Notice of Delisting or Transfer; Regulation FD Di | View | |
| 2023-12-26 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement | Agreement | View |
| 2023-12-20 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2023-12-19 | Departure/Election of Directors; Appointment of Officers; Regulation FD Disclosure; Financial Statem | View | |
| 2023-12-06 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2023-12-01 | Other Events; Financial Statements and Exhibits | View | |
| 2023-11-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-10-30 | Entry into Material Definitive Agreement; Termination of Material Definitive Agreement; Completion o | Agreement Acquisition | View |
| 2023-08-14 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-06-23 | Submission of Matters to a Vote of Security Holders | View | |
| 2023-05-11 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-05-01 | Regulation FD Disclosure; Financial Statements and Exhibits | View | |
| 2023-04-26 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2023-04-21 | Other Events; Financial Statements and Exhibits | View | |
| 2023-03-27 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2023-03-17 | Departure/Election of Directors; Appointment of Officers | View | |
| 2022-12-19 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Financial Statements and Exhibit | Agreement | View |
| 2022-12-13 | Departure/Election of Directors; Appointment of Officers; Financial Statements and Exhibits | View | |
| 2022-10-12 | Other Events | View | |
| 2022-05-12 | Results of Operations and Financial Condition; Regulation FD Disclosure; Financial Statements and Ex | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR